Precision BioSciences (NASDAQ: DTIL) announced a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025, to be delivered by Dr. Man-Fung Yuen, Chair Professor of Gastroenterology and Hepatology at The University of Hong Kong.
The presentation includes data from nine patients across 22 doses in the first three cohorts of the ongoing ELIMINATE-B Phase 1 study evaluating PBGENE-HBV, a first-in-class in vivo gene editing therapy designed to eliminate cccDNA, the root cause of chronic Hepatitis B, and inactivate integrated HBV DNA.
In a statement, Michael Amoroso, CEO of Precision, commented, “These new late-breaking data represent a milestone for Precision BioSciences and for the entire field of chronic Hepatitis B because it is the first time clinicians have been able to target the root viral source of the disease. The safety data and tolerability profile, along with dose-dependent durable reductions in hepatitis B surface antigen and the first liver biopsy data, provide evidence that antiviral activity is being achieved through directly editing the viral genome in patients with chronic Hepatitis B. This further validates ARCUS as a differentiated platform with true curative potential. With no observed dose-limiting toxicities to date, we look forward to finishing dosing the third cohort to generate additional data for PBGENE-HBV in our pursuit of a cure that has been so elusive in the field of Hepatitis B drug development.”
